Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: Assessing the risk of QT prolongation

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 2, 2012, Pages 144-149

  Murphy, Micheal E ^a   Singh, K P ^a   Laurenzi, M ^b   Brown, M ^c   Gillespie, S H ^a,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Global Alliance for TB Drug Development   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antimalarials; Fluoroquinolones; Malaria; Prolonged QT; Tuberculosis

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; BETA LACTAM ANTIBIOTIC; CHLOROQUINE; CLARITHROMYCIN; DOXYCYCLINE; GATIFLOXACIN; GREPAFLOXACIN; HALOFANTRINE; LEVOFLOXACIN; MEFLOQUINE; MOXIFLOXACIN; OFLOXACIN; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUINIDINE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFADOXINE; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIMALARIAL DRUG RESISTANCE; CARDIOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; ENDEMIC DISEASE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; MALARIA; MALARIA FALCIPARUM; MIXED INFECTION; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; TORSADE DES POINTES; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; HUMANS; INCIDENCE; MALARIA; RISK ASSESSMENT; RISK FACTORS; TORSADES DE POINTES; TUBERCULOSIS; WORLD HEALTH;

EID: 84863398227     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0074     Document Type: Review

References (22)

1. Lalloo D G, Shingadia D, Pasvol G, et al. UK malaria treatment guidelines. J Infect 2007; 54: 111-121. (Pubitemid 46083312)
2. Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States. Atlanta, GA, USA: CDC, 2009.
3. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.
4. White N J. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7: 549-558. (Pubitemid 47077715)
5. Supanaranond W, Davis T M, Pukrittayakamee S, Nagachinta B, White N J. Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. Eur J Clin Pharmacol 1993; 44: 325-329. (Pubitemid 23153448)
6. White N J, Looareesuwan S, Warrell D A, Warrell M J, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in c erebral and uncomplicated Falciparum malaria. Am J Med 1982; 73: 564-572. (Pubitemid 12003291)
7. Tran T H, Day N P, Nguyen H P, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83. (Pubitemid 26240108)
8. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-725. (Pubitemid 41207233)
9. Mzayek F, Deng H, Mather F J, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2: e6.
10. Ngouesse B, Basco L K, Ringwald P, Keundjian A, Blackett K N. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 2001; 65: 711-716. (Pubitemid 34051331)
11. Nosten F, ter Kuile F O, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341: 1054-1056. (Pubitemid 23114398)
12. Gupta R K, Van V M, Paiphun L, et al. Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate. Am J Trop Med Hyg 2005; 73: 267-268. (Pubitemid 41278695)
13. Bouchaud O, Imbert P, Touze J E, Dodoo A N, Danis M, Legros F. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J 2009; 8: 289.
14. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 2000; 94: 419-424. (Pubitemid 30662353)
15. Falade C, Makanga M, Premji Z, Ortmann C E, Stockmeyer M, de Palacios P I. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005; 99: 459-467. (Pubitemid 40521344)
16. Bindschedler M, Lefevre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M S. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 2000; 56: 375-381. (Pubitemid 30666063)
17. Bindschedler M, Lefevre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg 2002; 66: 293-298. (Pubitemid 34756099)
18. Lefevre G, Carpenter P, Souppart C, et al. Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects. J Clin Pharmacol 2002; 42: 1147-1158.
19. Lefevre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002; 54: 485-492. (Pubitemid 35356874)
20. Mytton O T, Ashley E A, Peto L, et al. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 2007; 77: 447-450. (Pubitemid 351844317)
21. von Seidlein L, Jaffar S, Greenwood B. Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 1997; 56: 494-497. (Pubitemid 27230068)
22. Kim K S, Lee H A, Cha S W, Kwon M S, Kim E J. Blockade of hERG K(+) channel by antimalarial drug, primaquine. Arch Pharm Res 2010; 33: 769-773.